Novartis suffers setback with failed cardiovascular drug trial

A Novartis drug aimed at lowering Lp(a) levels failed in a major clinical trial.

Published 4j1 sourceNotableupdated 12h

≈ 17sSpeed

The fact

The treatment targeted patients at high risk of heart attack and stroke.

The failure raises questions about cardiovascular drug development strategies.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on September 10, 2026